JEFFREY D CAPELLO
CIK 1224108 · EVP & Chief Financial Officer · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.35M
Companies
7
Total Filings
66
Lifetime Open-Market Net
-$13.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AGIO | Director | 10,865 | $35.99 | $391.0K | $0 | 7 | 2026-06-23 |
| NEOG | Director | 32,502 | $9.19 | $298.7K | $100.2K | 10 | 2025-10-29 |
| BIIB | EVP & Chief Financial Officer | 3,118 | $205.61 | $641.1K | $0 | 5 | 2020-02-14 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | — | — | — | $0 | 5 | 2018-07-06 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Director | — | — | — | $0 | 3 | 2017-07-27 |
| BSX | EVP & Chief Financial Officer | 447 | $46.06 | $20.6K | -$12.60M | 30 | 2013-12-02 |
| REVVITY, INC. (PKI) Delisted | SVP & CFO | 91,428 | $115.24 | $10.54M | -$989.9K | 4 | 2008-01-31 |
Recent Filings · Page 2 of 7
66 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-28 | NEOG | Grant (A) | +6,075 | $82.5K | EDGAR |
| 2024-10-09 | NEOG | Exer (M) | +2,070 | $31.2K | EDGAR |
| 2024-06-24 | AGIO | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | AGIO | Exer (M) | +1,976 | $0 | EDGAR |
| 2023-10-31 | NEOG | Exer (M) | — | $0 | EDGAR |
| 2023-06-15 | AGIO | Grant (A) | — | $0 | EDGAR |
| 2022-10-11 | NEOG | Exer (M) | — | $0 | EDGAR |
| 2020-02-14 | BIIB | Mixed | +1,305 | -$203.7K | EDGAR |
| 2020-01-06 | BIIB | Mixed | +896 | -$119.4K | EDGAR |
| 2019-02-14 | BIIB | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.